PharmSky is an integrated CDMO, based in Melbourne Australia. We provide integrated CMC development, from API and drug product development through to the manufacture and supply of clinical trial materials, supporting clinical‐stage companies

Our capabilities span multiple dosage forms, including sterile products, liquid and solid orals, with deep expertise in complex drugs such as liposomes and nanotechnology‐based formulations. Our facilities are built on ex‐Pfizer R&D operations, bringing years of hands‐on development experience. Eligible work may also qualify for Australia’s 43.5% R&D tax incentive.

Why work with us

PharmSky was established upon the acquisition of Pfizer R&D infrastructureinMelbourne,Australia, with our core team formed from ex-Pfizer and Hospira R&D experts.We deliver high-quality, efficient drug development, clinical supply and registration solutions for global biotech and pharmaceutical clients.Combining big-pharma scientific rigour with the speed and flexibility of a focused contract partner.

• We provided integrated services so you don't manage multiple vendors. We take you from API characterisation through formulation, analytical, manufacture, supply, distribution and storage —under a single project plan.
• We solve the formulation and process problems your internal teams or genericCDMOs can't. Deep expertise in challenging molecules, nano-systems, lipid delivery and high-potency APIs.
• We focus on the high-barrier end of the generics market —sterile injectables, lyophilised products, and complex parenterals where formulation IP and process know-how create defensible margin.